Real world data is becoming more vital
Post COVID-19, the need for medication to be administered in a home setting will be greater than ever. Without the provision of a connected solution however, there is an inherent risk that lifesaving medication will not be delivered with the necessary compliance, and as a result patient adherence will suffer. We must find a safe, secure and data driven way forward.
The changing landscape
During this webinar we will look at the impact of COVID-19 on clinical trials, patient recruitment, and monitoring; and the changing patient/ physician relationship. We will then focus on the power of digital health and the data that can be generated to support clinical trials.
Treatment at home
We will then look at the mainstream adoption of digital health in the home/everyday environment, discussing the benefits of training, onboarding, and diagnostics.
Scaling up for broader deployment
When moving from the clinical trial phase to mass adoption, there is a need to ensure solutions can scale. We will review the pitfalls, challenges, and benefits of digital health and how this can be delivered in the most sustainable way possible. COVID-19 has irreversibly changed the home administration landscape. This webinar will demonstrate how digital health solutions are an imperative to ensure safe, secure, efficient, and effective, patient outcomes. Please join us.
Presented by
Marcus Bates,
Director External Partners Connected Devices, Aptar Pharma
Marcus Bates has spent nearly 20 years working in the world of drug delivery devices and connected health. He has worked for two industry-leading companies in a range of roles and is currently responsible for the implementation of the supply chain for Aptar Pharma’s connected devices business, as well as leading business development activities in Europe.
Adam Shain,
Director Business Development Connected Devices, Aptar Pharma
Adam Shain is responsible for driving the new business agenda with pharma, payers and hospital network partners to reinforce the division’s leadership in the digital healthcare space. Adam previously worked for Promius Pharma, a subsidiary of Dr Reddy’s Laboratories, where he was instrumental in the development, commercialisation, and launch of many of its branded combination products.
Bernard Vrijens,
CEO AARDEX Group
Dr Bernard Vrijens is Chief Executive Officer at Advanced Analytical Research on Drug Exposure (AARDEX Group). He is also Invited Professor of Biostatistics at Liège University, Belgium. He holds a PhD from the Department of Applied Mathematics and Informatics at Ghent University, Belgium and currently leads research programs to enhance patient adherence. He is a founding member of the European Society for Patient Adherence, Compliance, and Persistence (ESPACOMP), and an active member of several collaborative projects around the theme of adherence to medications.
Tim Mcleroy,
Executive Director of Marketing and Patient Services, Noble, an Aptar Pharma company
Tim McLeroy has a wide breadth of medical and pharmaceutical experience over the past 25 years. This includes time working in the lab, sales in both hospitals and pharmaceuticals, international marketing and commercial development. His time also includes work in pipeline development and multiple product launches in combination products in big pharma and small. The past several years have focused on the customer experience and how this relates to adherence and compliance.
